Zhi Tong Cai Jing·2026-01-05 06:56Core Viewpoint - Rongchang Biopharma (09995) experienced a nearly 8% increase in stock price, reaching 79.3 HKD, with a trading volume of 405 million HKD, following news of potential new indications for its drug, Vidisicimab [1] Group 1: Drug Development and Clinical Trials - As of December 31, 2025, the CDE website indicates that Vidisicimab is proposed to be included as a breakthrough therapy for the first-line treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma, in combination with Trastuzumab and Toripalimab [1] - Vidisicimab has previously been recognized as a breakthrough therapy three times, and if this new indication is approved, it will mark the fourth recognition for the drug [1] - The company announced promising I/II phase clinical trial data for its self-developed PD-1/VEGF bispecific antibody RC148, showing significant clinical efficacy and manageable safety in both monotherapy and combination therapy for non-small cell lung cancer [1]